A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma
Single Center, Single Arm, Open Study, to Explore and Evaluate Treatment of Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
A PHASE2 clinical study on Intrahepatic Cholangiocarcinoma and Second-line Treatment, this trial is completed. The trial is conducted by Jiangsu HengRui Medicine Co., Ltd. and has accumulated 8 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Aug 2019 — Jan 2021 [monthly]
Completed PHASE2
Status: Recruiting → Completed · Phase: PHASE3 → PHASE2
-
Aug 2018 — Aug 2019 [monthly]
Recruiting PHASE3
▶ Show 3 earlier versions
-
Jul 2018 — Aug 2018 [monthly]
Recruiting PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE3
-
Sep 2017 — Jun 2018 [monthly]
Recruiting PHASE3
First recorded
Aug 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Jiangsu HengRui Medicine Co., Ltd.
- Peking Union Medical College Hospital
For direct contact, visit the study record on ClinicalTrials.gov .